Shuttle Pharmaceuticals Holdings, Inc. (SHPH) - Dilution Analysis

10-Q filing | 5.9M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. completed a merger with United Dogecoin Inc., issuing Series B-1 Preferred Stock and Pre-Funded Warrants as consideration, and closed a PIPE financing issuing Series B-2 Preferred Stock and Common Warrants. ($9.55M proceeds)

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. enters into a merger agreement with United Dogecoin Inc., issues Series B-1 Preferred Stock as merger consideration, engages in PIPE Financing involving Series B-2 Preferred Stock and warrants, and enters into a Second Amendment to an Asset Purchase Agreement, issuing additional Series B-1 Preferred Stock.

10-K filing | 5.6M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. issued 320,496 shares of common stock on December 23, 2025, as part of an accelerated payment for an asset purchase agreement.

10-Q filing | 1.6M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement to issue a pre-funded warrant to purchase up to 625,156 shares of common stock for gross proceeds of approximately $2.5 million in a private placement that closed on November 4, 2025. ($2.5M proceeds)

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. completed a private placement on June 24, 2025, involving the sale of 21,924 shares of common stock and 1,158,953 pre-funded warrants at a price of $3.60 and $3.599 respectively. ($4.25M proceeds)

10-Q filing | 10.0M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. closed a public offering of 1,340,921 shares of common stock at $0.30 per share and pre-funded warrants to purchase 17,825,746 shares of common stock at $0.299 per warrant, receiving net proceeds of approximately $5.2 million.

S-1/A filing: Filing for up to 10,000,000 shares of common stock and up to 10,000,000 pre-funded warrants.

10-K filing | 4.1M shares outstanding

S-1 filing: The company is filing an S-1 to offer common stock and pre-funded warrants to purchase common stock, with WestPark Capital, Inc. as the underwriter.

RW filing: Shuttle Pharmaceuticals Holdings, Inc. requests the withdrawal of their registration statement on Form S-1 (File No. 333-278535) because they have elected not to proceed with the offering at this time.

S-1 filing: This S-1 filing relates to the resale of common stock underlying convertible notes and warrants previously issued in a private placement, with the company not selling any securities and not receiving any proceeds from the sale, except for potential warrant exercises.

10-Q filing | 3.7M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. consummated a public offering of 395,574 shares of common stock and 2,555,246 pre-funded warrants, along with common stock purchase warrants to purchase up to 2,950,820 shares of common stock, for gross proceeds of approximately $4.5 million. ($4.5M proceeds)

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. completed an offering of convertible notes and warrants, closing an additional $231,579 in Notes and Warrants on October 21, 2024, bringing the total gross proceeds to $790,000.

S-1/A filing: This S-1/A filing registers up to 7,207,207 shares of common stock, pre-funded warrants, and common warrants for Shuttle Pharmaceuticals Holdings, Inc.

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. closed on $600,000 of an up to $1.3 million 5% original issue discount senior secured convertible note and warrant offering, issuing Convertible promissory notes and Warrants to purchase 286,169 shares of common stock exercisable at $1.53 per share. ($0.6M proceeds)

S-1 filing: This is a reasonable best efforts offering of up to $[\*] of shares of common stock, or Pre-Funded Warrants to purchase shares of common stock in lieu thereof, and warrants to purchase common stock at an assumed offering price of $[\_\_\_\_\_] per share of common stock, which is approximately equal to the last reported sale price per share of our common stock on the Nasdaq Capital Market on [\_\_\_\_\_], 2024.

10-Q filing | 2.1M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. implemented a 1-for-8 reverse stock split effective August 13, 2024, and amended its Securities Purchase Agreement with Alto Opportunity Master Fund, SPC involving a cash collateral payment and deferral of payments.

10-Q filing | 16.6M shares outstanding

S-1 filing: Shuttle Pharmaceuticals Holdings, Inc. is distributing to the holders of its common stock non-transferable rights to purchase up to an aggregate of $4,500,000 in units, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock, exercisable at $2.35 per share, and an interest in Shuttle Diagnostics, Inc.

10-K filing | 16.8M shares outstanding

10-Q filing | 15.7M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. entered into a consulting agreement with Joseph D. Armstrong, III, Ph.D., for his expertise on drug formulations and assistance with FDA meetings, compensating him with $1,500 per day and 100,000 restricted stock units.

10-Q filing | 14.3M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. entered into amendment no. 1 to the amendment agreement, for purposes of amending the terms of the Securities Purchase Agreement with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, releasing the remaining Cash Collateral totaling $2,924,000 to the Company. ($4.0M proceeds)

10-Q filing | 13.6M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. amended its Securities Purchase Agreement with Alto Opportunity Master Fund, SPC, releasing $1,500,000 in cash collateral to the Company and stipulating terms for a potential future sale of up to $10 million in convertible notes and warrants to Alto, and Shuttle Pharma received notice of approval for U.S. Patent No. 11,654,157.

10-K filing | 13.7M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holding, Inc. entered into a lease agreement for office and laboratory space and a director services agreement with Dr. Milton Brown, including options to purchase 25,000 shares of common stock.

S-1/A filing: This S-1/A filing registers the resale of shares of common stock underlying a convertible note and warrant issued in a private placement.

S-1 filing: This S-1 filing relates to the resale of common stock underlying a convertible note and warrant issued in a private placement.

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement with Alto Opportunity Master Fund, SPC, selling a $4.3 million convertible note and a warrant to purchase 1,018,079 shares of common stock for gross proceeds of $4.0 million; Boustead Securities, LLC received $320,000 cash compensation and a warrant to purchase 71,266 shares of Common Stock, exercisable at $2.35 per share as a placement agent. ($4.0M proceeds)

10-Q filing | 13.6M shares outstanding

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. closed its initial public offering on September 2, 2022, with the sale of 1,225,888 units at $8.125 per Unit, for gross proceeds of $9,960,340, and closed on the overallotment option on September 21, 2022, through the sale of an additional 183,883 Units at $8.125 per Unit, resulting in gross proceeds of $1,494,049. ($11.45M proceeds)

8-K filing: Shuttle Pharmaceuticals Holdings, Inc. closed a firm commitment initial public offering of 1,225,888 units, each consisting of one share of common stock and one warrant, at $8.125 per unit, with gross proceeds of $9,960,340. ($9.96M proceeds)

S-1/A filing: Initial public offering of 1,225,888 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at an assumed combined public offering price of $8.125 per unit.

S-1/A filing: This is an S-1/A filing for an initial public offering of Shuttle Pharmaceuticals Holdings, Inc., offering 1,245,000 units of securities, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at an assumed combined public offering price of $8.00 per unit.

S-1/A filing: Initial public offering of 1,660,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock at an assumed price of $6.00 per unit, for a total offering amount of $9,960,000.

S-1/A filing: This S-1/A filing details the initial public offering of Shuttle Pharmaceuticals Holdings, Inc., involving 2,500,000 shares of common stock, along with potential additional shares through underwriter options and conversions of preferred stock, warrants, and convertible notes.

S-1/A filing: This is an S-1/A filing for the initial public offering of common stock of Shuttle Pharmaceuticals Holdings, Inc., offering 3,000,000 shares of common stock with an estimated price between $4.50 and $5.00 per share.

S-1 filing: This is an S-1 filing for the initial public offering of Shuttle Pharmaceuticals Holdings, Inc., offering 3,000,000 shares of common stock at an estimated price between $4.50 and $5.00 per share.